Callio Therapeutics Launches $187 Million Series A
Deal News | Mar 03, 2025 | PR Newswire Cision Callio Therapeutics
Callio Therapeutics has launched with a Series A funding round of $187 million, spearheaded by Frazier Life Sciences, with participation from Jeito Capital and other leading life sciences investors including Novo Holdings A/S and Omega Funds. Based in Seattle and Singapore, Callio Therapeutics is focusing on developing multi-loader Antibody-Drug Conjugates (ADC) to address major medical needs in cancer therapy. The company has secured an exclusive global licensing agreement with Hummingbird Bioscience for their ADC platform. The funds will be used to achieve clinical proof of concept for their dual-load ADC targeting HER2 and another undisclosed program. Callio is led by experienced professionals in the biotechnology and pharmaceutical industries with a strong focus on enhancing patient outcomes through innovative therapies.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United States – Callio Therapeutics is based in Seattle, one of the primary locations mentioned in the article.
- Singapore – Hummingbird Bioscience, the partner for licensing agreements, is based in Singapore, highlighting the article's geographic relevance.
Industry
- Biotechnology – The article discusses Callio Therapeutics, which is a biotechnology company focused on cancer therapies through an innovative ADC platform.
- Pharmaceuticals – The involvement of developing therapies for cancer places Callio Therapeutics in the pharmaceutical industry, specifically connected to drug development.
- Venture Capital – The article involves significant investments by venture capital firms like Frazier Life Sciences and Jeito Capital into Callio Therapeutics.
Financials
- $187 million – The amount raised by Callio Therapeutics in its Series A funding round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Callio Therapeutics | Target Company | Company | A biotechnology company focusing on multi-loader ADC for cancer therapy. |
| Frazier Life Sciences | Lead Investor | Company | A venture capital firm leading the Series A funding for Callio Therapeutics. |
| Jeito Capital | Investor | Company | An investment firm participating significantly in Callio's Series A round. |
| Hummingbird Bioscience | Licensing Partner | Company | Company providing an exclusive licensing agreement for ADC platform to Callio. |
| Piers Ingram | CEO | Person | Co-Founder and CEO of Callio Therapeutics. |